Please assess the completion status of the following clinical trial:

Trial Title: Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of metastatic soft-tissue or bone sarcoma~* Ongoing complete response, partial response, or stable disease (RECIST) after a minimum of 4 cycles (and maximum of 12 months) of any one first, second, or third line of prior cytotoxic chemotherapy for metastatic disease~* Eastern Cooperative Oncology Group performance status of 0 or 1~* Adequate organ and bone marrow function~* Completed prior chemotherapy with last dose received at least 3 and up to 12 weeks prior to randomization~Exclusion Criteria:~* Prior therapy with rapamycin or rapamycin analogs~* Ongoing toxicity associated with prior anticancer therapy~* Another primary malignancy within the past three years~* Concomitant medications that induce or inhibit CYP3A~* Significant, uncontrolled cardiovascular disease

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ridaforolimus (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).